- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05201781
Un estudio a largo plazo para participantes tratados previamente con ciltacabtagene autoleucel
Estudio de seguimiento a largo plazo para participantes tratados previamente con ciltacabtagene autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Descripción general del estudio
Descripción detallada
Cilta-cel (JNJ-68284528/LCAR-B38M chimeric antigen receptor T-cells [CAR-T]) is an autologous CAR-T therapy that targets B-cell maturation antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. There will be no treatment administered during the study and the data obtained from this study will help to assess whether there will be long-term cilta-cel-related toxicities. The study will consist of 2 phases: within the first 5 years after receiving the last dose of cilta-cel and Year 6 to 15 years after last dose of cilta-cel. Safety evaluations will include a review of adverse events, laboratory test results, and physical examination findings (including neurological examination). The duration of the study is up to 15 years after last dose of cilta-cel and participants will be followed at least once per year.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Acceso ampliado
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Contact
- Número de teléfono: 844-434-4210
- Correo electrónico: Participate-In-This-Study1@its.jnj.com
Ubicaciones de estudio
-
-
-
Ghent, Bélgica, 9000
- Reclutamiento
- UZ Gent
-
Leuven, Bélgica, 3000
- Reclutamiento
- UZ Leuven
-
-
-
-
-
Pamplona, España, 31008
- Reclutamiento
- Clinica Univ. de Navarra
-
Salamanca, España, 37007
- Reclutamiento
- Hosp Clinico Univ de Salamanca
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Reclutamiento
- Mayo Clinic Cancer Center-Scottsdale
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope
-
San Francisco, California, Estados Unidos, 94143
- Reclutamiento
- University of California San Francisco
-
Stanford, California, Estados Unidos, 94305-5623
- Reclutamiento
- Stanford University Medical Center
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Reclutamiento
- University of Chicago
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Reclutamiento
- Indiana University
-
-
Kansas
-
Westwood, Kansas, Estados Unidos, 66205
- Reclutamiento
- Kansas University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Dana Farber Cancer Institute
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Reclutamiento
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55902
- Reclutamiento
- Mayo Clinic Rochester
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School Of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Reclutamiento
- Hackensack University Medical Center
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Reclutamiento
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Reclutamiento
- Roswell Park Cancer Institute
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10029
- Reclutamiento
- Mount Sinai Medical Center
-
The Bronx, New York, Estados Unidos, 10467
- Reclutamiento
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Reclutamiento
- Levine Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Reclutamiento
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Froedtert Memorial
-
-
-
-
-
Nord, Francia, 59037
- Reclutamiento
- CHRU de Lille Hopital Claude Huriez
-
Paris, Francia, 75010
- Reclutamiento
- Hopital Saint Louis
-
-
-
-
-
Tel Aviv, Israel, 64239
- Reclutamiento
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Nagoya, Japón, 467 8602
- Activo, no reclutando
- Nagoya City University Hospital
-
Shibuya City, Japón, 150-8935
- Activo, no reclutando
- Japanese Red Cross Medical Center
-
-
-
-
-
Amsterdam, Países Bajos, 1081 HV
- Reclutamiento
- VU Medisch Centrum
-
Groningen, Países Bajos, 9713 GZ
- Reclutamiento
- University Medical Center Groningen
-
-
-
-
-
Beijing, Porcelana, 100191
- Activo, no reclutando
- Peking University Third Hospital
-
Chengdu, Porcelana, 610041
- Activo, no reclutando
- West China Hospital Si Chuan University
-
Fuzhou, Porcelana, 350000
- Activo, no reclutando
- Fujian Medical University Union Hospital
-
Guangzhou, Porcelana, 510060
- Activo, no reclutando
- Sun Yat-sen University Cancer Hospital
-
Hangzhou, Porcelana, 310003
- Activo, no reclutando
- First Hospital, Zhejiang University Medical College
-
Nanjing, Porcelana, 210008
- Activo, no reclutando
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
Nanjing, Porcelana, 210029
- Activo, no reclutando
- Jiangsu Province Hospital
-
Shanghai, Porcelana, 200003
- Activo, no reclutando
- Shanghai Changzheng Hospital
-
Shanghai, Porcelana, 200434
- Activo, no reclutando
- Shanghai Fourth People s Hospital
-
Shanghai, Porcelana, 200025
- Activo, no reclutando
- Ruijin Hospital Shanghai Jiao Tong University
-
Xi'an, Porcelana, 710004
- Activo, no reclutando
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- Participants who have provided informed consent for this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cilta-cel
Participants who had previously received treatment with cilta-cel in a Company-sponsored clinical study (example, NCT04923893, NCT03758417, NCT04181827, NCT05347485, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended or a study has been terminated. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel. |
Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy
Periodo de tiempo: Up to 15 years
|
Number of participants with new malignancies and recurrence of pre-existing malignancy will be reported. |
Up to 15 years
|
|
Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder
Periodo de tiempo: Up to 15 years
|
Number of participants with new incidence or exacerbation of a pre-existing neurologic disorder will be reported. |
Up to 15 years
|
|
Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune Disorder
Periodo de tiempo: Up to 15 years
|
Number of participants with new incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder will be reported. |
Up to 15 years
|
|
Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including Hypogammaglobulinemia
Periodo de tiempo: From year 1 up to year 5
|
Number of participants with new incidence of Grade >=3 hematologic disorder including hypogammaglobulinemia will be reported. |
From year 1 up to year 5
|
|
Number of Participants with Serious Hematologic Disorder, including Hypogammaglobulinemia
Periodo de tiempo: From year 6 up to year 15
|
Number of participants with serious hematologic disorder, including hypogammaglobulinemia will be reported. Serious hematologic disorder, includes hypogammaglobulinemia (all grades, regardless of causality). |
From year 6 up to year 15
|
|
Number of Participants with New Incidence of Grade >= 3 Infection
Periodo de tiempo: From year 1 up to year 5
|
Number of participants with new incidence of Grade >=3 infection will be reported. |
From year 1 up to year 5
|
|
Number of Participants with Serious Infection
Periodo de tiempo: From year 6 up to year 15
|
Number of participants with serious infection will be reported. Serious infection includes all grades, regardless of causality. |
From year 6 up to year 15
|
|
Number of Participants with Serious Adverse Events (SAEs)
Periodo de tiempo: From year 1 up to year 5
|
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
From year 1 up to year 5
|
|
Number of Participants with Related Serious Adverse Events Assessed by the Investigator
Periodo de tiempo: From year 6 up to year 15
|
Number of participants with related serious adverse events assessed by the investigator will be reported. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
From year 6 up to year 15
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Peripheral Blood
Periodo de tiempo: Up to 15 years
|
Number of participants with measurable RCL in peripheral blood will be reported. |
Up to 15 years
|
|
Number of Participants with Chimeric Antigen Receptor (CAR) Transgene Level Greater Than (>) Lower Limit of Quantitation (LLOQ) in Peripheral Blood Cells
Periodo de tiempo: Up to 15 years
|
Number of participants with CAR transgene level >LLOQ in peripheral blood cells will be reported. |
Up to 15 years
|
|
Pattern of Lentiviral Vector Integration Sites
Periodo de tiempo: Up to 15 years
|
Pattern of lentiviral vector integration sites if at least 1 percent (%) of cells in the blood sample or new malignancy are positive for vector sequences will be reported. |
Up to 15 years
|
|
Investigator's Response Assessment of Long Term Follow-up on Chimeric Antigen Receptor T-cell (CAR-T) Therapy Based on Local Lab Assessments
Periodo de tiempo: Up to 15 years
|
Investigator's response assessment of long term follow-up on CAR-T therapy based on local lab assessments if the participant does not have confirmed disease progression or does not initiate subsequent anti-myeloma therapy at the entry of the study and at any time of during the study will be reported. |
Up to 15 years
|
|
Overall Survival (OS)
Periodo de tiempo: Up to 15 years
|
OS is measured from the date of randomization to the date of the participant's death. |
Up to 15 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Enfermedades hemic y linfáticas
- Mieloma múltiple
Otros números de identificación del estudio
- CR109123
- 2020-005521-84 (Número EudraCT)
- 68284528MMY4002 (Otro identificador: Janssen Research & Development, LLC)
- 2023-505530-10-00 (Identificador de registro: EUCT number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .